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Using the TβRIIΔk-ﬁ  b transgenic mouse model, Derrett-
Smith and colleagues [1] analyzed a potential role of 
transforming growth factor β (TGFβ) signaling in the 
vascular pathogenesis of systemic sclerosis (SSc).
SSc is a chronic autoimmune disease that aﬀ  ects the 
skin and various internal organs. Th   e most obvious histo-
pathological alteration of SSc is an extensive accumu-
lation of extracellular matrix [2]. Th  e resulting ﬁ  brosis 
disrupts the physiological tissue structure and frequently 
leads to dysfunction of the aﬀ  ected organs. Th  e  accumu-
lation of extracellular matrix in SSc patients is caused by 
activated ﬁ  broblasts [3]. In addition to ﬁ  brosis, vascular 
changes are a major hallmark of SSc. Th  ese may be 
classiﬁ  ed into a destructive- and a proliferative vasculo-
pathy. Th   e destructive vasculopathy aﬀ  ects small vessels 
and manifests early in the course of SSc as progressive 
loss of capillaries and insuﬃ   cient  angiogenesis.  Th  e 
clinical correlates of the destructive vasculopathy are 
Raynaud’s phenomenon and ﬁ  ngertip ulcers. In contrast, 
the proliferative vasculopathy is characterized by 
prolifera  tion of vascular cells with obstruction of the 
lumen, aﬀ  ects larger vessels like the pulmonary arteries 
and often manifests later in the course of the disease as 
pulmonary arterial hypertension [2].
Th   e key-role of TGFβ in ﬁ  brosis is well established as 
TGFβ signaling is activated in SSc. Activated TGFβ 
signaling stimulates the release of collagen in cultured 
ﬁ  broblasts and overexpression of a constitutively active 
TGFβ receptor type I in ﬁ  broblasts results in progressive 
ﬁ   brosis [3]. Moreover, inhibition of TGFβ signaling 
exerted potent anti-ﬁ  brotic  eﬀ   ects in diﬀ  erent  pre-
clinical models of SSc [4].
In contrast to ﬁ  brosis, only few data suggest a role of 
TGFβ in the vascular pathogenesis of SSc. First data from 
mouse models suggest that aberrant TGFβ signaling 
might not result in only ﬁ   brosis, but also in vascular 
alterations. Vascular changes have been described in 
several models with activated TGFβ signaling, such as 
caveolin-1 knockout mice and fos-related antigen (Fra-2) 
transgenic mice [5-8]. However, apart from Fra-2 
transgenic mice, the type of vessels involved and the 
histological changes diﬀ  er from those observed in human 
SSc.
Derrett-Smith and colleagues describe macrovascular 
changes in the thoracic aorta with altered gene expression 
in vascular smooth-muscle cells (vSMCs) in TβRIIΔk-ﬁ  b 
mice [1]. TβRIIΔk-ﬁ  b mice selectively express a kinase-
deﬁ  cient TGFβ receptor type II (TβRIIΔk) in ﬁ  broblasts 
under a ﬁ  broblast-speciﬁ  c pro-α2(I) collagen promoter 
[9]. Although overexpression of the kinase-deﬁ  cient 
TβRIIΔk construct interferes with TGFβ signaling in 
cultured ﬁ  broblasts in vitro, TβRIIΔk transgenic mice are 
characterized by activated TGFβ signaling and develop 
dermal and pulmonary ﬁ  brosis. Th  e molecular mecha-
nism underlying this paradoxical activation of TGFβ 
signaling in TβRIIΔk transgenic mice is incompletely 
characterized. Potential explanations include upregu-
lation of wild-type TβRII and TGFβ1 [9]. Th  e authors 
observed signs of activated TGFβ signaling in the aortas 
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© 2010 BioMed Central Ltdof TβRIIΔk-ﬁ   b mice with increased expression of 
latency-associated peptide-TGFβ1 (LAP-TGFβ1) and 
TGFβ1 in the adventitia and accumulation of phosphory-
lated Smad 2/3. Of note, TGFβ signaling was not 
restricted to ﬁ  broblasts, but was also observed in other 
cell types, such as smooth muscle cells. Consistent with 
activated TGFβ signaling, the collagen content of the 
thoracic aorta was increased and the adventitial and the 
smooth muscle cell layers were thickened. Th  ese  changes 
were functionally relevant and resulted in increased 
vascular stiﬀ  ness. Th   e contractility of isolated aortic rings 
upon incubation with KCl, α-adrenoreceptor agonists or 
thromboxane analogues was reduced in TβRIIΔk-ﬁ  b 
mice. Surprisingly, a partial TGFβ gene signature and 
increased contractility was also observed in vitro in early 
passage cultured aortic vSMCs, even though the TβRIIΔk 
transgene was not detectable in vSMCs [1].
Although the authors elegantly demonstrate vascular 
alterations in TβRIIΔk-ﬁ   b mice, additional studies are 
needed to establish increased TGFβ signaling in ﬁ  bro-
blasts as a molecular mediator of the vascular disease in 
SSc. Th   e molecular mechanisms by which the expression 
of the kinase-deﬁ  cient TβRIIΔk construct in ﬁ  broblasts 
activates TGFβ signaling in other cell types such as 
vSMCs are poorly understood. Th  us,  conﬁ  rmation of the 
altered phenotype of vSMCs in other models with 
ﬁ  broblast-speciﬁ  c activation of TGFβ signaling such as 
TβRICA Cre-ER mice would be important and might 
provide further mechanistic insights [10]. Furthermore, 
localization and the kinds of vascular changes in 
TβRIIΔk-ﬁ  b mice and also in most other animal models 
diﬀ   er from those in SSc patients. Derrett-Smith and 
coauthors describe vascular changes in the aorta of 
TβRIIΔk-ﬁ   b mice. However, the clinically relevant 
vascular manifestations in SSc aﬀ   ect the pulmonary 
arteries and the smaller vessels. Moreover, the histolo-
gical changes described in TβRIIΔk-ﬁ   b mice do not 
resemble the features of the destructive or proliferative 
vasculopathy in SSc. Does altered TGFβ signaling in 
ﬁ   broblasts also result in alterations of the pulmonary 
arteries, the small arteries and the capillaries and do the 
histological changes in these vessels resemble those 
observed in human SSc more closely? Th  e  demonstration 
of typical SSc-like changes in these vessels would further 
strengthen the importance of TGFβ signaling in the 
vascular pathology of SSc.
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